Broadfin Capital’s Heron Therapeutics HRTX Stock Holding History

Broadfin Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-100,000	Closed	-$1.85M	–	44
2019 Q3	$1.85M	Hold	100,000	–	–	0.34%	39
2019 Q2	$1.86M	Sell	100,000 -300,000	-75%	-$5.99M	0.4%	38
2019 Q1	$9.78M	Buy	+400,000	New	+$10.5M	2.02%	18
2018 Q4	–	Sell	-100,000	Closed	-$3.17M	–	54
2018 Q3	$3.17M	Hold	100,000	–	–	0.47%	44
2018 Q2	$3.88M	Buy	+100,000	New	+$3.18M	0.61%	37
2017 Q3	–	Sell	-300,900	Closed	-$4.17M	–	51
2017 Q2	$4.17M	Buy	+300,900	New	+$4.36M	0.51%	38
2016 Q4	–	Sell	-300,000	Closed	-$5.17M	–	66
2016 Q3	$5.17M	Buy	+300,000	New	+$5.57M	0.46%	52
2015 Q4	–	Sell	-500,000	Closed	-$12.2M	–	91
2015 Q3	$12.2M	Buy	+500,000	New	+$16.7M	0.68%	35

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Broadfin Capital's HRTX Position: Q4 2019 in Review

Broadfin Capital reduced its Heron Therapeutics (HRTX) stake by 8.7% in Q4 2019, selling an estimated $188K and leaving 89,730 shares worth $2.11M. The position accounts for 0.28% of the portfolio, ranked #38.

Broadfin Capital first reported a position in HRTX in Q1 2014 and has held it in 24 quarters since. The position peaked at $74.7M in Q2 2015. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

Broadfin Capital held 89,730 shares of Heron Therapeutics worth $2.11M as of Q4 2019.
Broadfin Capital sold 8,507 Heron Therapeutics shares in Q4 2019, an estimated $188K.
Heron Therapeutics made up 0.28% of Broadfin Capital's portfolio in Q4 2019, its #38 holding.
Broadfin Capital first reported a position in Heron Therapeutics in Q1 2014 and has held it in 24 quarters since.
Broadfin Capital's Heron Therapeutics position peaked at $74.7M in Q2 2015.
199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.